Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice

References

• Zhou Y, Penny HL, Kroenke MA, Bautista B, Hainline K, Chea LS, et al. Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology. J Immunother Cancer. 2022;10(4):e004225. doi:10.1136/jitc-2021-004225.
   PubMed Web of Science ®Google Scholar
• Dingman R, Balu-Iyer SV. Immunogenicity of Protein Pharmaceuticals. J Pharm Sci. 2019;108(5):1637–21. doi:10.1016/j.xphs.2018.12.014.
   PubMed Web of Science ®Google Scholar
• Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, et al. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. Journal for ImmunoTherapy of Cancer. 2019;7:105. doi:10.1186/s40425-019-0586-0.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, et al. Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021;12:626616. doi:10.3389/fimmu.2021.626616.
   PubMed Web of Science ®Google Scholar
• Bessa J, Boeckle S, Beck H, Buckel T, Schlicht S, Ebeling M, et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model. Pharm Res. 2015;32(7):2344–59. doi:10.1007/s11095-015-1627-0.
   PubMed Web of Science ®Google Scholar
• Boll B, Bessa J, Folzer E, Ríos Quiroz A, Schmidt R, Bulau P, et al. Extensive Chemical Modifications in the Primary Protein Structure of IgG1 Subvisible Particles Are Necessary for Breaking Immune Tolerance. Mol Pharm. 2017;14(4):1292–99. doi:10.1021/acs.molpharmaceut.6b00816.
   PubMedGoogle Scholar
• Bacac M, Klein C. Umana P. CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016;5(8):e1203498. doi:10.1080/2162402X.2016.1203498.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306–e. doi:10.1080/2162402X.2016.1277306.
   PubMed Web of Science ®Google Scholar
• Reitan SK, Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc Natl Acad Sci U S A. 2002;99(11):7588–93. doi:10.1073/pnas.052150899.
   PubMed Web of Science ®Google Scholar
• Ghetie V, Hubbard JG, Kim J-K, Tsen M-F, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice. Eur J Immunol. 1996;26(3):690–96. doi:10.1002/eji.1830260327.
   PubMed Web of Science ®Google Scholar
• Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A. 2008;105(27):9337–42. doi:10.1073/pnas.0801717105.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29(10):457–66. doi:10.1093/protein/gzw040.
   PubMed Web of Science ®Google Scholar
• Arnoult C, Brachet G, Cadena Castaneda D, Azzopardi N, Passot C, Desvignes C, et al. Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice. J Immunol. 2017;199(2):418–424. doi:10.4049/jimmunol.1601246.
   PubMed Web of Science ®Google Scholar
• Opolka-Hoffmann E, Jordan G, Otteneder M, Kieferle R, Lechmann M, Winter G, et al. The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance. mAbs. 2021;13(1):1995929. doi:10.1080/19420862.2021.1995929.
   PubMed Web of Science ®Google Scholar
• Hoffmann E, Kotsias F, Visentin G, Bruhns P, Savina A, Amigorena S. Autonomous phagosomal degradation and antigen presentation in dendritic cells. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(36):14556–61. doi:10.1073/pnas.1203912109.
   Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16(7):677–81. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Suurs FV, Lub-de Hooge MN, de Vries Ege, de Groot Dja. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103–19. doi:10.1016/j.pharmthera.2019.04.006.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2010;2(3):256–65. doi:10.4161/mabs.2.3.11641.
   PubMed Web of Science ®Google Scholar
• Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H, Brinks V. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. mAbs. 2012;4(6):740–52. doi:10.4161/mabs.22066.
   PubMed Web of Science ®Google Scholar
• Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, et al. Development of a Human Antibody Tolerant Mouse Model to Assess the Immunogenicity Risk Due to Aggregated Biotherapeutics. J Pharm Sci. 2013;102(10):3545–55. doi:10.1002/jps.23663.
   PubMed Web of Science ®Google Scholar
• Jawa V, Terry F, Gokemeijer J, Mitra-Kaushik S, Roberts BJ, Tourdot S, et al. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00011.
   PubMed Web of Science ®Google Scholar
• Bray-French K, Hartman K, Steiner G, Marban-Doran C, Bessa J, Campbell N, Martin-Facklam M, Stubenrauch K-G, Solier C, Singer T, et al. Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside. J Pharm Sci. 2021;110(7):2575–84. doi:10.1016/j.xphs.2021.03.027.
   PubMed Web of Science ®Google Scholar
• Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clinical Immunology. 2013;149(3):534–55. doi:10.1016/j.clim.2013.09.006.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg Pa, van de Stadt La, de Jong Rn, van Buren Eel, Kruithof S, de Groot E, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104. doi:10.1136/annrheumdis-2012-201445.
   PubMed Web of Science ®Google Scholar
• Stubenrauch K, Künzel C, Vogel R, Tuerck D, Schick E, Heinrich J. Epitope characterization of the ADA response directed against a targeted immunocytokine. J Pharm Biomed Anal. 2015;114:296–304. doi:10.1016/j.jpba.2015.05.029.
   PubMed Web of Science ®Google Scholar
• Cassotta A, Mikol V, Bertrand T, Pouzieux S, Le Parc J, Ferrari P, et al. A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients. Nat Med. 2019;25(9):1402–07. doi:10.1038/s41591-019-0568-2.
   PubMed Web of Science ®Google Scholar
• Bogen B, Dembic Z, Weiss S. Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J. 1993;12(1):357–63. doi:10.1002/j.1460-2075.1993.tb05664.x.
   PubMed Web of Science ®Google Scholar
• Jacobsen JT, Lunde E, Sundvold-Gjerstad V, Munthe LA, Bogen B. The cellular mechanism by which complementary Id+ Id + and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol. 2010;88(5):515–22. doi:10.1038/icb.2009.118.
   PubMed Web of Science ®Google Scholar
• Jacobsen JT, Sundvold-Gjerstad V, Skjeldal FM, Andersen J-T, Abrahamsen G, Bakke O, et al. B-cell tolerance to the B-cell receptor variable regions. Eur J Immunol. 2013;43:2577–87. doi:10.1002/eji.201243203.
   PubMed Web of Science ®Google Scholar
• Jacobsen J, Haabeth OA, Tveita AA, Schjetne KW, Munthe LA, Bogen B. Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells. J Immunol. 2014;192(9):4174–83. doi:10.4049/jimmunol.1302359.
   PubMed Web of Science ®Google Scholar
• Hummel H-D, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, et al. Pasotuxizumab, a BiTE® BiTE ® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. 2021;13(2):125–41. doi:10.2217/imt-2020-0256.
   PubMed Web of Science ®Google Scholar
• You G, Won J, Lee Y, Moon D, Park Y, Lee SH, et al. Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines. 2021;9(7):724. doi:10.3390/vaccines9070724.
   Web of Science ®Google Scholar
• Reitan SK, Hannestad K. The primary IgM antibody repertoire: a source of potent idiotype immunogens. Eur J Immunol. 2001;31(7):2143–53. doi:10.1002/1521-4141(200107)31:7<2143::AID-IMMU2143>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551–59. doi:10.1093/intimm/13.12.1551.
   PubMed Web of Science ®Google Scholar
• Melendez R, Ordonia B, Guerrero J, Hassanzadeh A, Tran P, Low J, Wong M, Brumm J, Chung S, Kamen L, et al. Introducing dendritic cell antibody internalization as an immunogenicity risk assessment tool. Bioanalysis. 2022;14(10):703–13. doi:10.4155/bio-2022-0024.
   PubMed Web of Science ®Google Scholar
• Colombetti S, Benigni F, Basso V, Mondino A. Clonal Anergy Is Maintained Independently of T Cell Proliferation. The Journal of Immunology. 2002;169(11):6178. doi:10.4049/jimmunol.169.11.6178.
   PubMed Web of Science ®Google Scholar
• Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21(1):305–34. doi:10.1146/annurev.immunol.21.120601.141110.
   PubMedGoogle Scholar
• Yamamoto T, Hattori M, Yoshida T. Induction of T-cell activation or anergy determined by the combination of intensity and duration of T-cell receptor stimulation, and sequential induction in an individual cell. Immunology. 2007;121(3):383–91. doi:10.1111/j.1365-2567.2007.02586.x.
   PubMed Web of Science ®Google Scholar
• Bessa J, Jegerlehner A, Hinton HJ, Pumpens P, Saudan P, Schneider P, et al. Alveolar Macrophages and Lung Dendritic Cells Sense RNA and Drive Mucosal IgA Responses. The Journal of Immunology. 2009;183(6):3788. doi:10.4049/jimmunol.0804004.
   PubMed Web of Science ®Google Scholar
• Hoffmann E, Jordan G, Lauer M, Ringler P, Kusznir EA, Rufer AC, et al. Generation, Characterization, and Quantitative Bioanalysis of Drug/Anti-drug Antibody Immune Complexes to Facilitate Dedicated In Vivo Studies. Pharm Res. 2019;36(9):129. doi:10.1007/s11095-019-2661-0.
   PubMed Web of Science ®Google Scholar
• Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215(3):403–10. doi:10.1016/S0022-2836(05)80360-2.
   PubMed Web of Science ®Google Scholar
• Madaan A, Verma R, Singh AT, Jain SK, Jaggi M. A stepwise procedure for isolation of murine bone marrow and generation of dendritic cells. Journal of Biological Methods. 2014;1(1):e1. doi:10.14440/jbm.2014.12.
   Google Scholar
• R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.
   Google Scholar